2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
By D. Arnett, R. Blumenthal, M. Albert, E. Michos, Andrew B. Buroker, M. Miedema, Z. Goldberger, D. Muñoz, E. Hahn, Sidney C. Smith and 26 more. Journal of the American College of Cardiology, 2019
4,134 citations recorded by the source corpus.
Author(s): Arnett, Donna K; Blumenthal, Roger S; Albert, Michelle A; Buroker, Andrew B; Goldberger, Zachary D; Hahn, Ellen J; Himmelfarb, Cheryl D; Khera, Amit; Lloyd-Jones, Donald; McEvoy, J William; Michos, Erin D; Miedema, Michael D; Munoz, Daniel; Smith, Sidney C; Virani, Salim S; Williams, Kim A; Yeboah, Joseph; Ziaeian, Boback
Subfields: Cardiology and Cardiovascular Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/a046daa116020f482eeb94c97daa89571833bf3c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Surgery
Citations in the corpus
- Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association (2023, background): “67a The 2022 American College of Cardiology/AHA/Heart Failure Society of America guidelines for the management of HF included for the first time a Class of Recommendation 2a, Level of Evidence B-NR to consider validated multivariable scores to estimate the risk of incident HF. 90 It is well…”
- A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association (2023, methodology): “…high-risk patients with diabetes and ASCVD on maximally tolerated statins who have not achieved a 50% reduction of LDL-C or with an LDL-C >70 mg/dL. 62,63 American and European guidelines differ on the use of PCSK9 inhibitors for primary prevention; European guidelines support consideration of…”
- NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications (2020, neutral): “142 Presently, there is disagreement between different professional societies as to what constitutes ‘sufficient’ CVD risk (to prescribe statins), but in the above guidelines ‘sufficient’ CVD risk is defined as ≥7.5% risk of developing a CVD event over 10 years.”